Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
Introduction Obesity is a complex, multifactorial condition characterized by an excessive accumulation of body fat. It is widely recognized as a major public health issue due to its strong association with numerous chronic diseases. [1][2] The use of GLP-1 receptor agonists in obesity treatment...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-12-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846106793968664576 |
|---|---|
| author | Karolina Baran Marlena Jankowska Natalia Jańczyk Karolina Mędrysa Jakub Pokrzepa Michał Presak Gabriela Blecharz Julia Szwech Alicja Winkowska Jan Machalica |
| author_facet | Karolina Baran Marlena Jankowska Natalia Jańczyk Karolina Mędrysa Jakub Pokrzepa Michał Presak Gabriela Blecharz Julia Szwech Alicja Winkowska Jan Machalica |
| author_sort | Karolina Baran |
| collection | DOAJ |
| description | Introduction
Obesity is a complex, multifactorial condition characterized by an excessive accumulation of body fat. It is widely recognized as a major public health issue due to its strong association with numerous chronic diseases. [1][2]
The use of GLP-1 receptor agonists in obesity treatment began with the recognition that these drugs, initially developed for type 2 diabetes, could significantly reduce body weight due to their effects on appetite regulation and satiety. Liraglutide was the first to be approved specifically for obesity, followed by semaglutide, The development of tirzepatide, which targets both GLP-1 and GIP receptors, has further expanded the potential for obesity treatment. As clinical evidence continues to support their efficacy and safety, GLP-1 receptor agonists are becoming an important tool in the management of obesity, offering a promising option for individuals struggling with weight and related health conditions [3][4][5].
Aim of the study
The aim of this study was to compare the effectiveness of semaglutide, liraglutide and tirzepatide in reducing body weight in obesity.
Materials and methods
The article was created based on the PubMed and Cochrane databases. The literature was analyzed using the fallow keywords: Obesity treatment, liraglutide, tirzepatide, semaglutide, glucagon-like peptide-1 (GLP-1) receptor agonists
Results
The research proved that tirzepatide is more effective in reducing body weight compared to semaglutide and liraglutide [6][7].
Conclusion
Thanks to the comparison of results from multiple studies, we can assume that, at this point, tirzepatide is the most effective pharmacological treatment for obesity, which, when used in combination with lifestyle changes, provides a lasting effect on weight reduction and, consequently, helps treat obesity-related comorbidities[6][8].
|
| format | Article |
| id | doaj-art-363ec2c174544a4389d642b11ba2f3d4 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-363ec2c174544a4389d642b11ba2f3d42024-12-27T08:21:39ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-12-013010.12775/QS.2024.30.56469Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature reviewKarolina Baranhttps://orcid.org/0009-0004-1627-5065Marlena Jankowskahttps://orcid.org/0009-0005-2240-8853Natalia Jańczykhttps://orcid.org/0009-0000-1862-9681Karolina Mędrysahttps://orcid.org/0009-0002-1557-0244Jakub Pokrzepahttps://orcid.org/0009-0000-7907-1511Michał Presakhttps://orcid.org/0009-0006-0335-5917Gabriela Blecharzhttps://orcid.org/0009-0007-9275-3913Julia Szwechhttps://orcid.org/0009-0006-3792-0101Alicja Winkowskahttps://orcid.org/0009-0005-2050-0031Jan Machalicahttps://orcid.org/0009-0007-0943-7312Introduction Obesity is a complex, multifactorial condition characterized by an excessive accumulation of body fat. It is widely recognized as a major public health issue due to its strong association with numerous chronic diseases. [1][2] The use of GLP-1 receptor agonists in obesity treatment began with the recognition that these drugs, initially developed for type 2 diabetes, could significantly reduce body weight due to their effects on appetite regulation and satiety. Liraglutide was the first to be approved specifically for obesity, followed by semaglutide, The development of tirzepatide, which targets both GLP-1 and GIP receptors, has further expanded the potential for obesity treatment. As clinical evidence continues to support their efficacy and safety, GLP-1 receptor agonists are becoming an important tool in the management of obesity, offering a promising option for individuals struggling with weight and related health conditions [3][4][5]. Aim of the study The aim of this study was to compare the effectiveness of semaglutide, liraglutide and tirzepatide in reducing body weight in obesity. Materials and methods The article was created based on the PubMed and Cochrane databases. The literature was analyzed using the fallow keywords: Obesity treatment, liraglutide, tirzepatide, semaglutide, glucagon-like peptide-1 (GLP-1) receptor agonists Results The research proved that tirzepatide is more effective in reducing body weight compared to semaglutide and liraglutide [6][7]. Conclusion Thanks to the comparison of results from multiple studies, we can assume that, at this point, tirzepatide is the most effective pharmacological treatment for obesity, which, when used in combination with lifestyle changes, provides a lasting effect on weight reduction and, consequently, helps treat obesity-related comorbidities[6][8]. https://apcz.umk.pl/QS/article/view/56469obesity treatmentliraglutydtirzepatidesemaglutideGLP-1 receptor agonist |
| spellingShingle | Karolina Baran Marlena Jankowska Natalia Jańczyk Karolina Mędrysa Jakub Pokrzepa Michał Presak Gabriela Blecharz Julia Szwech Alicja Winkowska Jan Machalica Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review Quality in Sport obesity treatment liraglutyd tirzepatide semaglutide GLP-1 receptor agonist |
| title | Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review |
| title_full | Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review |
| title_fullStr | Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review |
| title_full_unstemmed | Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review |
| title_short | Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review |
| title_sort | semaglutide liraglutide and tirzepatide comparison of effectiveness in the treatment of obesity a literature review |
| topic | obesity treatment liraglutyd tirzepatide semaglutide GLP-1 receptor agonist |
| url | https://apcz.umk.pl/QS/article/view/56469 |
| work_keys_str_mv | AT karolinabaran semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT marlenajankowska semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT nataliajanczyk semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT karolinamedrysa semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT jakubpokrzepa semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT michałpresak semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT gabrielablecharz semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT juliaszwech semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT alicjawinkowska semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview AT janmachalica semaglutideliraglutideandtirzepatidecomparisonofeffectivenessinthetreatmentofobesityaliteraturereview |